Lille (France), Boston (Massachusetts, United States), January 27th, 2015 – GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces its tentative financial calendar for 2015, which is set as follows:
February 20, 2015: Publication of revenue for Q4 2014, and cash position as of December 31, 2014
February 24, 2015: Combined General Shareholders’ Meeting in Lille
April 3, 2015: Publication of 2014 financial statements
May 7, 2015: Publication of revenue for Q1 2015, and cash position as of March 31, 2015
June 3, 2015: Annual Shareholders’ Meeting in Lille
September 25, 2015: Publication of financial statements as of June 30, 2015
November 6, 2015: Publication of revenue for Q3 2015, and cash position as of September 30, 2015
About GENFIT:
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT’s R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT’s lead proprietary compound, GFT505, that is completing a Phase 2b study in NASH. With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com
Help employers find you! Check out all the jobs and post your resume.
